*.- TRABECTEDIN FOR INOPERABLE OR RECURRENT SOFT TISSUE SARCOMA IN ADULT PATIENTS .Fernando A. Angarita1; Amanda J. Cannell, BScH1; Albiruni R. Razak3; Brendan C. Dickson2; Martin E. Blackstein1
1Medicial Oncology, Mount Sinai Hospital, Toronto, ON, Canada; 2Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; 3Drug Development Program, Princess Margaret Cancer Center, Toronto, ON, Canada
Conclusion: Trabectedin has a manageable safety profile in a clinical setting. The use of this agent demonstrated encouraging disease control in different groups of STS patients.
*********************************************
*.- STRATIFIED EFFICACY ANALYSIS AND PHARMACOKINETIC (PK) ANALYSIS OF TRABECTEDIN FROM A RANDOMIZED PHASE II STUDY COMPARING TRABECTEDIN AND BEST SUPPORTIVE CARE (BSC) IN PATIENTS (PTS) WITH TRANSLOCATION-RELATED SARCOMAS (TRS) .
Takafumi Ueda, MD, PhD1; Shunji Takahashi2; Nobuhito Araki3; Hideshi Sugiura4; Tsukasa Yonemoto5;
Mitsuru Takahashi6; Hideo Morioka7; Toru Hiruma8; Hiroaki Hiraga9; Toshiyuki Kunisada10; Akihiko Matsumine, MD, PhD11;
Takanori Tanase12; Akira Kawai13
1Dept of Orthopaedic Surgery, Osaka National Hospital, Osaka, Japan; 2Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 3Orthopaedic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; 4Orthopaedic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; 5Orthopaedic Surgery, Chiba Cancer Center, Chiba, Japan; 6Orthopaedic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan; 7Orthopaedic Surgery, School of Medicine, Keio University, Tokyo, Japan; 8Musculoskeletal Tumor Surgery, Kanagawa Cancer Center, Yokohama, Japan; 9Orthopaedic Surgery, Hokkaido Cancer Center, Sapporo, Japan; 10Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; 11Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan; 12Data Science, Taiho Pharmaceutical CO., LTD, Tokyo, Japan; 13Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan
Conclusion: Trabectedin is an active drug in TRS pts pretreated by available chemotherapies with a significant increase in PFS regardless of histological subgroups related to sensitivity to chemotherapy.
*******************************************
*.- MECHANISTIC RATIONALE FOR COMBINING TRABECTEDIN WITH ANTI-IGF1R AGENTS IN EWING SARCOMA : EVIDENCES OF AN EFFECTIVE THERAPY .
Katia Scotlandi, PhD1; AnaTeresa Amaral3; Cecilia Garofalo1; Enrique deAlava3; Maurizio D’Incalci2
1Experimental Oncology, Istituto Rizzoli, Bologna, Italy; 2Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 3Pathology, 1Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Sevilla, Spain .
Conclusion: We demonstrate that trabectedin may not only inhibit but also enhance the binding of EWS-FLI1 to some target genes. The up-regulation of IGF-1R after treatment with trabectedin provides the rationale for an effective combined therapy with anti-IGF-1R inhibitors.